Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure to treat hematopoietic disorders. Current bone marrow conditioning protocols create space for healthy donor stem cells by employing irradiation and/or chemotherapy, but carry severe toxicities, resulting in significant morbidity, mortality and substantial long-term complications. To develop a low-toxicity solution, we generated a bi-specific T-cell engager (BTCE) that targets CD117, an abundantly expressed receptor on hematopoietic stem and progenitor cells (HSPC) and leukemia-initiating cells (LICs). We show that the CD117×CD3 BTCE efficiently depletes in vitro and in vivo HSPCs and LICs. The CD117×CD3 BTCE was not toxic and facilitates highly efficient engraftment of human allogenic donor CD34+cells in humanized mice, thereby restoring hematopoiesis in vivo in both normal and leukemia-bearing humanized mice. We demonstrate here that a potent CD117×CD3 BTCE enables rapid HSCT in both benign and malignant conditions.

Czech Academy of Sciences Prague Czech Republic

Department of Hematology Erasmus MC Universitair Medisch Centrum Rotterdam Rotterdam The Netherlands

Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

Department of Pediatric Haematology and Oncology Harbour Biomed Shanghai Co Ltd Shanghai Shanghai China

Department of Pediatric Haematology and Oncology Motol University Hospital Department of Pediatrics Prague Czech Republic

Harbour Biomed Shanghai Co Ltd Shanghai Shanghai China

Zobrazit více v PubMed

Baldomero H, Neumann D, Hamad N, et al. The role of registries in hematological disorders. Best Pract Res Clin Haematol. 2024;37:101556. doi: 10.1016/j.beha.2024.101556. PubMed DOI

Goebel GA, de Assis CS, Cunha LAO, et al. Survival After Hematopoietic Stem Cell Transplantation in Severe Combined Immunodeficiency (SCID): A Worldwide Review of the Prognostic Variables. Clin Rev Allergy Immunol. 2024;66:192–209. doi: 10.1007/s12016-024-08993-5. PubMed DOI

Lum SH, Eikema D-J, Piepenbroek B, et al. Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia. Blood. 2024;144:1329–42. doi: 10.1182/blood.2023022751. PubMed DOI

Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–64. doi: 10.1038/s41409-021-01227-8. PubMed DOI PMC

Testi AM, Moleti ML, Angi A, et al. Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review. Pediatric Health Med Ther . 2023;14:197–215. doi: 10.2147/PHMT.S366636. PubMed DOI PMC

Yabe H, Koike T, Yamamoto S, et al. Allogeneic stem cell transplantation for inherited metabolic disorders: 35 years’ experience at a single institution. Int J Hematol. 2024;120:365–74. doi: 10.1007/s12185-024-03810-3. PubMed DOI

Sawyer J, Elliott T, Orton L, et al. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int . 2024;6:1–10. doi: 10.46989/001c.94952. PubMed DOI PMC

Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344–53. doi: 10.1182/blood-2014-02-514778. PubMed DOI PMC

Raber-Durlacher JE, Treister NS, Zadik Y, et al. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation. Support Care Cancer. 2024;32:545. doi: 10.1007/s00520-024-08685-y. PubMed DOI PMC

Al-Mahayri ZN, AlAhmad MM, Ali BR. Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies? Front Oncol. 2021;11:710163. doi: 10.3389/fonc.2021.710163. PubMed DOI PMC

Roganovic J, Haupt R, Bárdi E, et al. Late Adverse Effects after Treatment for Childhood Acute Leukemia. Acta Med Acad. 2024;53:59–80. doi: 10.5644/ama2006-124.438. PubMed DOI PMC

Ferrari S, Valeri E, Conti A, et al. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 2023;30:549–70. doi: 10.1016/j.stem.2023.04.014. PubMed DOI

Domen J, Weissman IL. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. J Exp Med. 2000;192:1707–18. doi: 10.1084/jem.192.12.1707. PubMed DOI PMC

Czechowicz A, Kraft D, Weissman IL, et al. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007;318:1296–9. doi: 10.1126/science.1149726. PubMed DOI PMC

Chhabra A, Ring AM, Weiskopf K, et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med. 2016;8:351ra105. doi: 10.1126/scitranslmed.aae0501. PubMed DOI PMC

Bankova AK, Pang WW, Velasco BJ, et al. 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Adv. 2021;5:3900–12. doi: 10.1182/bloodadvances.2020003841. PubMed DOI PMC

Czechowicz A, Palchaudhuri R, Scheck A, et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun. 2019;10:617. doi: 10.1038/s41467-018-08201-x. PubMed DOI PMC

Uchida N, Stasula U, Demirci S, et al. Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model. Nat Commun. 2023;14:6291. doi: 10.1038/s41467-023-41153-5. PubMed DOI PMC

Magnani CF, Myburgh R, Brunn S, et al. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther Oncolytics. 2023;30:56–71. doi: 10.1016/j.omto.2023.07.003. PubMed DOI PMC

Arai Y, Choi U, Corsino CI, et al. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment. Mol Ther. 2018;26:1181–97. doi: 10.1016/j.ymthe.2018.03.003. PubMed DOI PMC

Bubb QR, Balood M, Seir GE, et al. Development of multivalent CAR T cells as dual immunotherapy and conditioning agents. Mol Ther Oncol . 2025;33:200944. doi: 10.1016/j.omton.2025.200944. PubMed DOI PMC

Volta L, Myburgh R, Hofstetter M, et al. A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells. Hemasphere. 2024;8:e70055. doi: 10.1002/hem3.70055. PubMed DOI PMC

Casirati G, Cosentino A, Mucci A, et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature New Biol. 2023;621:404–14. doi: 10.1038/s41586-023-06496-5. PubMed DOI PMC

Kwon H-S, Logan AC, Chhabra A, et al. Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood. 2019;133:2104–8. doi: 10.1182/blood-2018-06-853879. PubMed DOI PMC

Jung D, Long-Boyle JR, Pang WW, et al. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplant Cell Ther. 2024;30:923. doi: 10.1016/j.jtct.2024.07.001. PubMed DOI

Salerno SN, Deng R, Kakkar T. Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency. CPT Pharmacometrics Syst Pharmacol. 2022;11:1316–27. doi: 10.1002/psp4.12847. PubMed DOI PMC

Agarwal R, Dvorak CC, Prohaska S, et al. Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning. Biol Blood Marrow Transplant. 2019;25:S92. doi: 10.1016/j.bbmt.2018.12.172. DOI

Baeuerle PA, Kufer P, Lutterbüse R. Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther. 2003;5:413–9. PubMed

Broudy VC, Lin N, Zsebo KM, et al. Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood. 1992;79:338–46. PubMed

Blumberg RS, Ley S, Sancho J, et al. Structure of the T-cell antigen receptor: evidence for two CD3 epsilon subunits in the T-cell receptor-CD3 complex. Proc Natl Acad Sci U S A. 1990;87:7220–4. doi: 10.1073/pnas.87.18.7220. PubMed DOI PMC

Minutti CM, Piot C, Pereira da Costa M, et al. Distinct ontogenetic lineages dictate cDC2 heterogeneity. Nat Immunol. 2024;25:448–61. doi: 10.1038/s41590-024-01745-9. PubMed DOI PMC

Li K, Du Y, Cai Y, et al. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia. Leukemia. 2023;37:308–25. doi: 10.1038/s41375-022-01789-6. PubMed DOI PMC

Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–703. doi: 10.1200/JCO.2002.20.6.1692. PubMed DOI

Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577–85. doi: 10.1182/blood-2016-10-696054. PubMed DOI PMC

Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature New Biol. 1994;367:645–8. doi: 10.1038/367645a0. PubMed DOI

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7. doi: 10.1038/nm0797-730. PubMed DOI

Gandhi A, Lee CJ, Varma A, et al. Allogeneic transplantation: conditioning regimens, engraftment and acute toxicities. Blood. 2023;142:470–2. doi: 10.1182/blood-2023-185533. DOI

Polisetti N, Schlötzer-Schrehardt U, Reinhard T, et al. Isolation and enrichment of melanocytes from human corneal limbus using CD117 (c-Kit) as selection marker. Sci Rep. 2020;10:17588. doi: 10.1038/s41598-020-74869-1. PubMed DOI PMC

Nishida H, Daa T, Kashima K, et al. KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors. Am J Dermatopathol. 2015;37:898–905. doi: 10.1097/DAD.0000000000000301. PubMed DOI PMC

Myburgh R, Kiefer JD, Russkamp NF, et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia. 2020;34:2688–703. doi: 10.1038/s41375-020-0818-9. PubMed DOI

Lammie A, Drobnjak M, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42:1417–25. doi: 10.1177/42.11.7523489. PubMed DOI

Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376:836–47. doi: 10.1056/NEJMoa1609783. PubMed DOI PMC

Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387:495–505. doi: 10.1056/NEJMoa2203478. PubMed DOI PMC

Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570–6. doi: 10.1038/s41591-023-02589-w. PubMed DOI PMC

Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387:2220–31. doi: 10.1056/NEJMoa2206913. PubMed DOI

Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023;41:2238–47. doi: 10.1200/JCO.22.01725. PubMed DOI PMC

Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055–65. doi: 10.1016/S1470-2045(22)00335-7. PubMed DOI

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387:2232–44. doi: 10.1056/NEJMoa2204591. PubMed DOI

Omer MH, Shafqat A, Ahmad O, et al. Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers (Basel) 2023;15:4550. doi: 10.3390/cancers15184550. PubMed DOI PMC

Haber L, Olson K, Kelly MP, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11:14397. doi: 10.1038/s41598-021-93842-0. PubMed DOI PMC